HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bertil Olofsson Selected Research

Hyperkalemia

12/2008Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
2/2008Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
11/2007Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
10/2004Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bertil Olofsson Research Topics

Disease

20Heart Failure
07/2010 - 09/2003
5Hypotension (Low Blood Pressure)
12/2008 - 09/2003
4Hyperkalemia
12/2008 - 10/2004
4Stroke (Strokes)
08/2005 - 05/2003
3Hypertension (High Blood Pressure)
01/2009 - 01/2002
2Cognitive Dysfunction
08/2005 - 05/2003
1Atrial Fibrillation
07/2006
1Anemia
02/2006
1Sudden Death
10/2005
1Unstable Angina
10/2005
1Myocardial Infarction
10/2005
1Diabetes Mellitus
07/2005
1Left Ventricular Dysfunction
10/2004
1Isolated Systolic Hypertension
09/2004
1Cough
09/2003
1Dementia (Dementias)
05/2003

Drug/Important Bio-Agent (IBA)

25candesartanIBA
07/2010 - 05/2003
8Angiotensin Receptor AntagonistsIBA
07/2010 - 10/2004
7Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
02/2008 - 09/2003
5Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
05/2006 - 09/2003
4CreatinineIBA
08/2009 - 10/2004
3Pharmaceutical PreparationsIBA
12/2008 - 10/2004
3Antihypertensive Agents (Antihypertensives)IBA
08/2005 - 05/2003
2Hemoglobins (Hemoglobin)IBA
08/2008 - 02/2006
2Spironolactone (Aldactone)FDA LinkGeneric
02/2008 - 11/2007
2AngiotensinsIBA
02/2008 - 07/2005
2Mineralocorticoid Receptor AntagonistsIBA
02/2008 - 10/2004
2Angiotensin II Type 1 Receptor BlockersIBA
09/2004 - 09/2003
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
07/2010
1Angiotensin Receptors (Angiotensin II Receptor)IBA
07/2010
1AlbuminsIBA
08/2009
1Hydrochlorothiazide (Esidrix)FDA LinkGeneric
01/2009
1PotassiumIBA
11/2007
1Glucose (Dextrose)FDA LinkGeneric
07/2005
1ReninIBA
07/2005
1Angiotensin IIIBA
09/2004
1candesartan cilexetil (Amias)FDA Link
01/2002

Therapy/Procedure

8Therapeutics
01/2009 - 05/2003
1Drug Tapering
11/2007